Skip to content
Federal Budget, Medical Health Aged Care

ANZGOG welcomes the Federal Budget’s investment in medical research and clinical trials and highlights the need for continued focus on gynaecological cancers

Australia New Zealand Gynaecological Oncology Group (ANZGOG) 2 mins read

MEDIA RELEASE 
FOR IMMEDIATE RELEASE 

 

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) welcomes key initiatives in the Federal Budget that will support Australians living with gynaecological cancer. This includes investment in medical research, clinical trials, Pharmaceutical Benefits Scheme (PBS), Medicare and support for our healthcare workers. 

 

ANZGOG acknowledges the Federal Government’s commitment of $158.6 million over five years to support medical research and the translation of research into clinical practice, alongside the $150.3 million investment in expanding precision oncology programs, including the Australian Rare Cancers Portal. These investments represent a positive step in strengthening Australia’s healthcare system and advancing cancer care. 

 

However, with 19 women diagnosed with a gynaecological cancer every day, and more than half facing a rare or less common cancer with limited treatment options and poor survival rates, ANZGOG recognises the critical need for increased investment and collaboration in this area to change treatment, catalyse research and save women’s lives. 

 

ANZGOG Chair, Professor Clare Scott AM, said the organisation is committed to working with government and the broader health sector to ensure women with gynaecological cancers receive the same level of research investment and treatment innovation as those diagnosed with other cancers. 

 

"With the number of Australian women impacted by gynaecological cancer rising, it is essential that we continue to strengthen research and clinical trial investment to drive better outcomes. ANZGOG stands ready to collaborate with government, the health sector, and research partners to support, connect and implement these important initiatives." 

 

ANZGOG looks forward to working with the Federal Government to build on these Budget measures, as well as partnering with the Medical Research Future Fund, the Australian Cancer Plan, and the National Framework for Genomics in Cancer Control.   

 

Through targeted investment and transformative research, we can improve the diagnosis, treatment, and care of gynaecological cancers—delivering better outcomes for all those affected. - ENDS - 


About us:

About ANZGOG: The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the peak national gynaecological cancer research organisation in Australia and New Zealand. Our vision is: Advancing research, Saving Lives. The group has more than 1500 members representing clinical, allied health and pure research specialties, and includes community. ANZGOG clinical trials are conducted at over 80 hospital sites and include both local and global collaborations to ensure the best research is available to improve life for women with a gynaecological cancer. 


Contact details:

Media inquiries: Monique Cerreto T: 0416 282 464 E: [email protected]  

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.